Lead Product(s) : Saposin C,Dioleoyl Phosphatidylserine
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a cell membrane phospholipid used for solid tumors and...
Brand Name : BXQ-350
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 29, 2021
Lead Product(s) : Saposin C,Dioleoyl Phosphatidylserine
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?